E' disponibile il nuovo numero del BD&L Journal
| view it online | ||
ihlg NEWSLETTER |
||
 |
||
 |
||
| Business development networking group for the healthcare industry |
||
IL BD&L JOURNAL E' DISPONIBILE ALLA LETTURACari Colleghi, è uscito il nuovo numero del BD&L Journal - Issue 34 January 2022. Potete consultarlo accedendo all'area riservata (Materiali/BD Journal). In questo numero: Co-development and Co-commercialisation Alliances: Learnings and suggested ways of working (Jon Bell and Kay Tait, AstraZeneca) Pharma Transactions During the COVID-19 Pandemic - how resilient were they? (John Easton, Sedulus UK) Launching a Drug in Canada: Business, pricing and legal considerations (Manon Decelles, Pharmdside Strategic Business Advisors; Neil Palmer and Dylan Lamb Palmer, PDCI Market Access and Eileen McMahon, Torys LLP) The Dragon and the Tiger: Case study of a Chinese biopharma working with an Indian CRO (Hanlan Liu and Xiahui Wang, Sperogenix Therapeutics; Arunika Singhal, Integral Biosciences and Ravi Sodha, Sodha Pharma Consulting) In Conversation With... Linda Bradley, LifeArc (Umaima Ahmad, PLG UK) "In this inaugural issue of 2022 we focus in on dealmaking over the course of the pandemic, through a report on the resilience of deal terms during this time, and by taking a look at learnings from the major antibody-drug conjugate alliance deals between AstraZeneca and Daiichi Sankyo, including one negotiated virtually in 2020. We speak with LifeArc’s Head of Business Development, Linda Bradley, and learn about the medical research charity’s commitment to spend £1.3bn on the sector by 2030 including through translational challenges, much of which is likely to be executed through strategic partnerships. We hear from Canadian market access subject matter experts on how to launch a drug in Canada, looking particularly at pricing strategies and recent proposals for legislative change. Finally, we cross to the other side of the world for a case study on a rare drug development deal between an Indian CRO and Chinese biopharma company."  |
||
|
BD and Licensing executives operating in the Italian healthcare sector meets at IHLG. Providing a stimulating environment, IHLG fosters the development of good relationships and strategic alliances/partnerships among companies and institutions giving its members the ideal conditions to:
• drive new business opportunities; • exchanging valuable experiences at national and international level; • develop knowledge and expertise in the complex areas of licensing and BD. IHLG promotes the professional development of its members through the organization on semesterly basis of courses, meetings and seminars. Italy HLG - Healthcare Licensing Group Via Fabio Filzi, 19 - 20124 Milano - Italy www.italyhlg.it - info@italyhlg.it |
||
| WWW.ITALYHLG.IT | CONTACT US | GALLERY | ||
| unsubscribe | ||
